Interview: Madhusudhan Venkatachari – CEO, Natco Pharma Canada
Madhu Venkat, CEO of Natco Pharma Canada, highlights the company’s portfolio strategy, its strategic road map to be the first mover and become a leading generic supplier in oncology by…
Address: NATCO HOUSERoad No.2, Banjara HillsHyderabad-500 033,India
Tel: +91-40-2354 7532
Web: http://www.natcopharma.co.in/
NATCO Pharma Limited is an Indian enterprise molded by global aspirations. This has always demanded a preparedness and long- term organizational vision that can encompass the turbulence’s and paradoxes of shifting terms and terrain’s of business.
Background
Beginning:- NATCO PHARMA was promoted by Mr. V.C. Nannapaneni in the year 1981 as a Private Limited Company to be in the business of Research, Developing, Manufacturing and Marketing of Pharmaceutical Substances and Finished Dosage forms for Indian and International markets. NATCO PHARMA began operations in 1984 in Andhra Pradesh, India.
First Success:- In the first year of its operations it achieved a sales figure of Rs. 0.5 million. The company’s first product was Cardicap, which is an Anti-Anginal drug. Since then the company has introduced many dosage forms into the market. By 1985 it had dosage forms in Cardiovascular, Anti-cold, Anti-Asthmatic and Antibiotic segments. NATCO has the credit of having pioneered Time Release Technology in India.
The Journey:- NATCO PHARMA was ranked 82nd in sales among Indian Pharmaceutical companies in 1994. NATCO also has the credit of being one of the largest contract manufacturers in India. Some of the well-known companies like Ranbaxy, Dr. Reddy’s Laboratories, John Wyeth etc. get their products manufactured by NATCO. NATCO PHARMA grew in size when three companies merged with it.
NATCO Parenterals Limited
Dr. Karanth Pharma Labs Private Limited
NATCO Laboratories Limited
Today:- NATCO PHARMA LIMITED, which began its operations as a single unit with 20 employees, today has four manufacturing facilities and employs around 1500 people. It has an on-line data for Analysis and decision making. Consistently ranked among the fastest growing pharmaceutical companies in the country, Natco is utilizing its collective experience to kick start its future plans as a global company. Respected for Quality, Performance, Care, Responsibility and for creation and maximization of wealth for its shareholders NATCO Pharma Limited, the post-merger organization represents a strategic stage in NATCO’s constant evolution as the Complete Pharma Company.
TIGI
URINAT
PRIMANAT
AMINAT
VORIZOL
NATCLOVIR
NATFLU
X-VIR
BUNIDE-CR
OMENAT
NATZOLD
BANDRONE 150
Madhu Venkat, CEO of Natco Pharma Canada, highlights the company’s portfolio strategy, its strategic road map to be the first mover and become a leading generic supplier in oncology by…
Compared to 5 years ago, MNCs have increased their presence in India. Some even have become market leaders, particularly through acquisitions of domestic players. How is this redistributing the game…
As managing director of India’s fifth largest pharmaceutical company, Zydus Cadila’s Sharvil Patel shares his insights on his impressive internationalization strategy with a special focus on the US where Zydus…
A successful commercial leader, Annaswamy Vaidheesh, president of OPPI, VP South Asia and managing director at GSK India, talks about the tremendous work that the local affiliate is doing in…
A strong supporter of public-private partnerships, MSD’s managing director in India, Vivek Kamath, explains how the company’s collaborative approach is the key to enhancing their reputation, improving patient outcomes and…
Ashok Battacharya, executive director of the Indian affiliate of Takeda Pharmaceuticals, with 38 years experience in global Ppharmaceutical MNCs, discusses the top-notch reputation that Takeda has among physicians and patients…
Think global, act local! This is the Novartis business approach in India. A great believer in stakeholder collaboration, Jawed Zia, country president of Novartis India, explains how co-marketing deals with…
Deloitte predicts that the global market for biosimilars will reach between USD 25 and 35 billion by 2020, driven by some key global biologic drugs facing loss of exclusivity in…
Alexandre Williams, founder and managing director of Athena, an international company with an Indian manufacturing basis specialized in life cycle products, provides insights into some key trends shaping India’s pharmaceutical…
As the founder and chairman of Alves Group, a key Indian player in medical devices with an extensive portfolio, Randolph Alves shares the challenges India needs to overcome to remain…
Dharmesh Shah, managing director of BDR Pharmaceuticals, a company with a strong expertise in oncology, intensive care, and other therapeutic areas, provides us with an insightful overview of the main…
For multinational companies, despite ‘pharmerging markets’ not holding the hype and allure they once did, India still stands as a land of opportunity for a variety of reasons. Novartis India…
Umang Vohra, managing director and global CEO of Indian pharma giant Cipla, discusses the company’s ambition to grow in both the domestic and emerging markets as well as the opportunities…
Nikhil Masurkar, executive director of Entod Pharmaceuticals, talks about the company’s ambition to invest in stem cell research and become market leaders in the field of ophthalmology in ten years’…
See our Cookie Privacy Policy Here
